Show notes Clinical Implementation of GLP-1 Receptor Agonists What were the groundbreaking findings of the STEP1 and SURMOUNT-1 trials and how these impact cardiovascular wellness
While the removed fat cells do not regenerate, weight gain can cause the remaining cells to expand
Nat Med 32 , 599608 (2026)
1, 2023, Caprara emailed several key staffers in the governors office to convene a meeting for a discussion about state health insurance coverage (as well as other health insurance plans) of drugs like Ozempic, wegovy and mounjaro. Theres no record in the documents turned over by Pritzkers office of any involvement by the governor himself in the decision to cover the drugs
Although dual and triagonist medications have so far exhibited side effects comparable to those of GLP- 1 receptor monoagonists in human trials, these preclinical findings imply that GIP receptor agonism may be the secret to obtaining the weight loss advantages of incretin agonism with less severe side effects
IL18R1 has been shown to activate P65, which then translocates to the nucleus to promote the transcription of pro-inflammatory genes 32
